In brief
Three years ago, 23andMe was a thriving tech giant, known for revolutionizing DNA testing and gaining celebrity endorsements. Today, however, its share price has plummeted from $321 to below $5, prompting questions about its viability. Experts suggest the firm lacks a sustainable business model, as its once lucrative DNA reports provided little long-term engagement. The company's attempt to monetize an anonymized DNA database for drug research has also lagged, creating further instability. As leadership changes loom, speculation about potential sales has emerged, but 23andMe insists on remaining independent. Moreover, concerns over the security of invaluable genetic data amplify the stakes, as the ramifications of data breaches extend beyond individual users.
